Gemini Therapeutics Completes 60 Patients Enrollment In Lead Candidate Mid-Stage Study In Dry AMD

by Vandana Singh, Benzinga Editor

February 10, 2021 12:07 PM | 1 min read | Make a Comment

Gemini Therapeutics Inc (NASDAQ: GMTX) concludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H (CFH), in dry Age-related macular degeneration (AMD) patients with CFH loss-of-function gene variants.
The 60-subject trial is designed to evaluate safety and tolerability and measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers. Topline data anticipated in the first half of 2021.
The FDA granted Fast Track Designation for GEM103 to treat dry AMD in patients with CFH loss of function gene variants.
Price Action: GMTX shares moved 2.95% higher at 13.27 during market hours on the last check Wednesday.

Posted In: Biotech News FDA General Age-Related Macular Degeneration Phase 2A Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.